Waiving Vaccine IP Doesn't Affect Market Assessment
Following the news the Biden administration supports a proposed waiver on intellectual property protection for COVID-19 vaccines, we are not changing our FVEs to COVID-19 vaccine firms.
We're not making changes to our fair value estimates or moat ratings for COVID-19 vaccine firms following the May 5 announcement that the Biden administration supports a proposed waiver on intellectual property protection for COVID-19 vaccines. The proposal to waive patent rights during the pandemic was initially made to the World Trade Organization by India and South Africa in October. With the pandemic raging in India and Brazil, calls to support this proposal have strengthened, and U.S., Europe, and U.K. opposition has become a potential political liability. It could take months to finalize the proposal, and Europe and U.K. have yet to support the waiver.
Beyond IP, we see huge skill and supply-related barriers to designing and building efficient mRNA manufacturing at scale outside of global leaders Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA), and their contract manufacturing networks. Moderna disclosed in October that it would not enforce its COVID-19 patents during the pandemic but has not seen any signs of copycat production globally, which we think supports the idea barriers to production beyond IP. Using raw materials in short supply (like lipids) for riskier efforts at new facilities rather than for established networks could result in reduced global supply in 2021 and 2022.
After incorporating updates from Moderna and Pfizer with first-quarter earnings, we have raised our forecast for COVID-19 vaccine sales to $70 billion in 2021 (from $67 billion as of April 22). Beyond 2021, both Moderna and Pfizer/BioNTech are negotiating new contracts, and they remain best positioned to develop the first vaccines against new variants. Moderna has released the first data for a third dose with its mRNA-1273.351 variant vaccine that imply stronger and more consistent protection across variants, and Pfizer expects data from its own variant vaccine in July. Pfizer also noted that future variant vaccine updates may only need a lead time until regulatory authorization of roughly 100 days.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Karen Andersen does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.